Kornimate/medical-research-clean huggingface dataset:
epidemiology of digital nerve injuries in the stockholm county

Conditions: Digital Nerve Injury

Summary: this is a registry and medical record based epidemiological description of patients with digitial nerve injuies in the stockholm county, sweden

the primary aim of this study was to describe the epidemiology of patients with surgically repaired digital nerve injuries in a swedish population during the period 2012 to 2018. secondary aims included a description of the patient population, surgical treatment and rehabilitation regimens following digital nerve injury. comparisons were made between groups consisting in patients with isolated nerve injuries and those with a concomitant flexor tendon injury. methods patients in this cohort study, all patients treated with surgical repair of a digital nerve injury at the department of hand surgery at södersjukhuset, stockholm, sweden were included. inclusion period was between 2012-01-01 and 2018-12-31. patients were identified through the swedish national quality registry for hand surgery (hakir). inclusion criteria were the diagnostic codes (icd-10) for a digital nerve injury in the thumb (s64.3) or finger (s64.4) in combination with the surgical code (kkå97) nomesco classification of surgical procedures for nerve repair (acb29). a total of 1,329 patients were identified. exclusion criteria were concomitant skeletal injury, amputations, severe soft tissue injuries, or if the injury needed microvascular reconstruction. patients reciding outside the stockholm region and children below 18 years of age were also excluded. a total of 1,004 patients were included for the final analysis. the study population was thereafter divided into two groups: patients with an isolated digital nerve injury and patients with a ditial nerve injry with a concomitant tendon injury. all clinical data was collected through search of medical records.

Eligibility criteria:
inclusion criteria: * diagnostic codes (icd-10) for a digital nerve injury in the thumb (s64.3) or finger (s64.4) in combination with the surgical code (kkå97) nomesco classification of surgical procedures for nerve repair (acb29). exclusion criteria: * concomitant skeletal injury * amputations * severe soft tissue injuries * injury needed microvascular reconstruction. * patients reciding outside the stockholm region and * patient age below 18 years of age
mucin balls and corneal inflammation events

Conditions: Corneal Inflammation; Corneal Infiltrative Events

Summary: the purpose of this study is to determine if the formation of mucin balls is a marker for protection from inflammatory events to the cornea and if mucin balls play a role in protection during extended contact lens wear.


Eligibility criteria:
inclusion criteria: * at least 18 years * free of any active anterior segment disorders that would preclude safe contact lens wear. active anterior segment disorders and evidence of central microbial keratitis (via a large, \>1mm central deep stromal scar) are not allowed. however, evidence of past contact lens-induces peripheral ulcer (clpu) will be allowed so long as no more then three such scars are detected bilaterally. evidence of more than 3 clpu-like scars places excessive risk on the subject for a subsequent corneal infiltrate event (cie). * correctable vision to 20/25 or better in each eye with spectacles. amblyopia will be excluded. * flat and steep corneal curvatures from keratometry readings must be between 39.00 and 48.50 d, respectively. * own or agree to purchase a pair of spectacles that can be worn when lenses are removed or in cases of ocular discomfort or emergency. * correctable vision to 20/30 or better at distance with dispensed contact lenses. exclusion criteria: * use/wear of rigid gas permeable lenses within the last 30 days or poly (methyl methacrylate) (pmma) lenses within the last 3 months. * immunocompromising disease or insulin dependent diabetes or any other systemic disease that in the investigator's opinion will affect ocular health or increase risk during extended wear. * chronic use of systemic corticosteroids (with the exception of corticosteroid inhalers) or any other medication that in the investigator's opinion will affect ocular physiology or study participation. * ocular disease or condition such as aphakia, corneal dystrophies, corneal edema, external ocular infection, iritis, or had any anterior segment surgery. * use of any ocular medications in the last 2 weeks. * less than or equal to grade 2 on any of the slit lamp observations of: upper tarsal papilla, corneal staining, corneal neovascularization, conjunctival injection, and lid erythema or scales. * currently pregnant or lactating. * smoker * swimming routine of more than twice per month.
culturing tm cells from primary open-angle glaucoma patient biopsies

Conditions: Glaucoma

Summary: in this study, the investigators will collect tissue from patients undergoing trabeculectomy for primary open-angle glaucoma treatment. this tissue would normally be discarded. these trabecular meshwork (tm) cells can be cultured and used experimentally to better understand the mechanisms of glaucoma. these tm biopsies will be cultured on the same day as the trabeculectomy using established techniques.


Eligibility criteria:
inclusion criteria: * patients having glaucoma and undergoing a trabeculotomy * sign icf (informed consent form) exclusion criteria: * none
the effect of different molecular weight of ha for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: recently, nerve hydrodissection is utilized to assist ultrasound-guided nerve injection and studies recommend its clinical benefit for peripheral entrapment neuropathy. hyaluronic acid (ha) can decrease the post-surgery adhesion of soft tissue and nerve but its clinical application in clinical practice is very rare. we just proved that single ha injection have short-term effectiveness in mild-to-moderate carpal tunnel (cts) cases and this finding may hint the therapeutic effectiveness of nerve hydrodissection for cts depend on absorption time of solution. in addition, no study compare different weight of ha for nerve injection so far. hence, the purpose of this study aim to compare different weight of ha for cts and whether hydrodissection effect depend on the absorption time of solution or not.

participants established with diagnosis of mild-to-moderate cts will been randomly assigned to high molecular weight ha (aragan plus, 20 mg/2 ml, 3000kda) or low molecular weight ha (artzdispo, 25 mg/2.5 ml, 600-1200kda) groups. with ultrasound guidance, total two-sessions of high or low molecular weight ha with one week interval will been injected into intra-carpal region. the boston carpal tunnel syndrome questionnaire is assigned as primary outcome. the secondary outcomes encompass visual analog scale, electrophysiological studies, cross-sectional area of the median nerve, mobility of median nerve and absorption time of ha. the assessment is performed prior injection and at 2 week, 1, 2, 3 and 6 months post-injection.

Eligibility criteria:
inclusion criteria: * age between 20-80 year-old. * diagnosis was confirmed using an electrophysiological study exclusion criteria: * cancer * coagulopathy * pregnancy * inflammation status * cervical radiculopathy * polyneuropathy, brachial plexopathy * thoracic outlet syndrome * previously undergone wrist surgery or steroid injection for cts

Keywords: hydrodissection hyaluronic acid
a multicenter pediatric deep brain stimulation registry

Conditions: Dystonia; Epilepsy in Children; Cerebral Palsy; Tourette Syndrome; Obsessive-Compulsive Disorder; Neurologic Disorder; Movement Disorders in Children; Movement Disorders; Deep Brain Stimulation

Summary: there is limited data on outcomes for children who have undergone deep brain stimulation (dbs) for movement disorders, and individual centers performing this surgery often lack sufficient cases to power research studies adequately. this study aims to develop a multicenter pediatric dbs registry that allows multiple sites to share clinical pediatric dbs data. the primary goals are to enable large-scale, well-powered analyses of the safety and efficacy of dbs in the pediatric population and to further explore and refine dbs as a therapeutic option for children with dystonia and other hyperkinetic movement disorders. given the current scarcity of evidence available to clinicians, this centralized multicenter repository of clinical data is critical for addressing key research questions and improving clinical practice for pediatric dbs.

the use of deep brain stimulation (dbs) has expanded to include multiple conditions in children including dystonia, epilepsy, tourette syndrome and mood disorders. despite its growing application, dbs remains a low-volume procedure in most pediatric centers, which limits opportunities for large-scale research studies. to overcome this challenge, an international data-sharing platform is essential for advancing knowledge about dbs in pediatric patients, particularly concerning surgical techniques and patient outcomes across various conditions. this study aims to establish a multicenter pediatric dbs registry. with limited data on pediatric dbs outcomes and a small number of cases at individual centers, there is a need for a comprehensive registry to enable large-scale, well-powered analyses of dbs safety and effectiveness. the primary goals of this study are to: * establish and implement a multi-center pediatric dbs registry * facilitate large-scale analyses of dbs safety and effectiveness in children * refine dbs as a treatment option for dystonia and other hyperkinetic movement disorders in children. secondary objectives include: * identifying which patients benefit most from dbs * determining clinical variables that influence dbs responsiveness * identifying optimal implant sites for specific conditions * understanding the long-term effects of dbs in children * assessing the impact of dbs on the quality of life in pediatric patients the study will involve both prospective and retrospective data collection from pediatric dbs patients.

Eligibility criteria:
inclusion criteria: * female or male patients between ages of 0-18 years. * having received or scheduled to receive dbs for any neurological movement disorder. * parents or legal guardians are able to provide written consent for prospective enrollment.

Keywords: deep brain stimulation dbs movement disorder movement disorders in children dystonia chorea dyskinesia epilepsy
study of bortezomib (velcade) in combination with dexamethasone to treat patients with relapsed hodgkin's lymphoma

Conditions: Hodgkin Disease

Summary: the primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed hodgkin's lymphoma.

the proteasome-inhibitor bortezomib (velcade) shows promising activity in various human lymphoma cell line. in addition, several studies in heavily pretreated patients with lymphoma showed also promising results.

Eligibility criteria:
inclusion criteria: * hodgkin's lymphoma * second or higher relapse (first relapse if high-dose chemotherapy not possible) * age \>/= 18 years * no major organ dysfunction or intercurrent disorder * written informed consent exclusion criteria: * pregnant or nursing

Keywords: hodgkin disease bortezomib relapse lymphoma
treatment of women after postpartum haemorrhage

Conditions: Postpartum Haemorrhage

Summary: the primary purpose of this study is to compare the efficacy of iv high single dose infusion of iron isomaltoside 1000 to standard medical care in women with pph evaluated as physical fatigue.


Eligibility criteria:
inclusion criteria: 1. women with pph ≥ 700 and ≤ 1000 ml or pph \> 1000 ml and hb \> 6.5 g/dl (4.0 mmol/l) measured \> 12 hours after delivery 2. willingness to participate and signed the informed consent form exclusion criteria: 1. women aged \< 18 years 2. multiple births 3. peripartum rbc transfusion 4. known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis) 5. known hypersensitivity to parenteral iron or any excipients in the investigational drug products 6. women with a history of active asthma within the last 5 years or a history of multiple allergies 7. known decompensated liver cirrhosis and active hepatitis 8. women with hellp (haemolysis elevated liver enzymes low platelet count) syndrome (defined according to "dansk selskab for obstetrik og gynækologi guidelines") 9. active acute infection assessed by clinical judgement 10. rheumatoid arthritis with symptoms or signs of active joint inflammation 11. history of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency) 12. not able to read, speak and understand the danish language 13. participation in any other clinical study where the study drug has not passed 5 half-lives prior to the baseline 14. any other medical condition that, in the opinion of the investigator, may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study. for example, a malignancy, uncontrolled hypertension, unstable ischaemic heart disease or uncontrolled diabetes mellitus
study evaluating the safety,tolerability and efficacy of pf-04360365 in adults with probable cerebral amyloid angiopathy

Conditions: Cerebral Amyloid Angiopathy

Summary: cerebral amyloid angiopathy (caa) is a condition caused by the build-up of a protein called amyloid, predominantly aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain. probable caa may be defined as two or more hemorrhages in the brain cortex in individuals 55 years of age or older. this study will examine the study drug (pf-04360365) vs. placebo (saline) at 10 mg/kg - day 1 and the maintenance dose of the study drug (pf-04360365) vs. placebo (saline) at 7.5mg/kg on days 30 and 60. subjects will be followed for 6 months after receiving the last dose of study medication.


Eligibility criteria:
inclusion criteria: * patients diagnosed with probable caa using the boston criteria; with no clinical cognitive impairment * in general good health exclusion criteria: * co-morbid diagnosis of clinically documented alzheimer's disease or significant cognitive impairment * clinically significant syncope, epilepsy, head trauma or clinically significant unexplained loss of consciousness within the last 5 years * subject's body weight exceeding 100kg * women of childbearing potential.

Keywords: cerebral amyloid angiopathy (caa) cerebrovascular reactivity functional mri randomized double blind safety efficacy
mitomycin c versus bacillus calmette-guerin in the intravesical treatment of non-muscle-invasive bladder cancer patients

Conditions: Bladder Cancer

Summary: the purpose of this study is to compare the bladder cancer treatments, mitomycin c (mmc) and bacillus calmette guerin (bcg), to find out which is better. in this study, the patient will get either the mitomycin c (mmc) or the bacillus calmette guerin (bcg). they will not get both. the patient had a transurethral resection (tur) or an in office cystoscopy to make the diagnosis of bladder cancer. a biopsy was done and removed any tumors the doctor saw. even after the doctor removes the tumors, the cancer can return. in this case, the doctor will put medicine into the bladder to destroy cancer cell. this is called intravesical therapy. the two most commonly used drugs for this purpose are mmc and bcg. both drugs have been studied for many years. they both show good results when compared to other treatments. they have not been studied using the schedule that will be used in the study. the doctor does not know if these two drugs are equally effective in treating the cancer and preventing recurrence. bcg has been studied more often than mmc. the studies have shown that a long schedule of bcg is better than a short schedule of mmc. they have also shown that the side effects of bcg are more intense than with mmc. a recent study showed that a new dose of mmc is better than the old standard dose. since the side effects of mmc occur less often, it is important to learn whether the two drugs are equally effective. that could help us decide between the treatments. in this study, the doctor will compare mmc and bcg when given for the same amount of time. the doctor hopes the study will tell us which drug is more effective in preventing the return of the cancer.


Eligibility criteria:
inclusion criteria: * age 18 years or older * patients must have pathologically confirmed non-muscle invasive urothelial bladder carcinoma by the department of pathology new york presbyterian hospital, weill medical college of cornell university or memorial sloan kettering cancer center or a documented past history of ta or t1 non-muscle invasive urothelial bladder tumors. * intermediate risk ubc patients: recurrence total score = 1 to 9 exclusion criteria: * any intravesical therapy within the past six months prior to current diagnosis * currently being treated or scheduled to have radiation treatment for bladder cancer during the study * scheduled to have surgery for bladder cancer during the study * currently being treated or scheduled to have treatment with any chemotherapeutic agent during the study

Keywords: bladder mitomycin c mmc theracysr bacillus calmette-guerin bcg intravesical 09-118
non-invasive positive pressure (nppv ) for severe stable chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Hypercapnic Respiratory Failure

Summary: assessment of the effect and safety of noninvasive positive pressure ventilation for severe stable chronic obstructive pulmonary disease


Eligibility criteria:
inclusion criteria: * clinically stable, hypercapnic gold stage iv copd, aged 18 years or older, baseline arterial carbon dioxide pressure (paco2) of 6.7 kpa (50 mmhg) or higher and a ph higher than 7·35, measured after at least 1 h rest in a sitting position. exclusion criteria: * thorax or the lung other than copd * no smoking or cigarette≤10/day * obesity with a bodymass index (bmi) ≥40 kg/m² * malignant co-morbidities,severe heart failure (new york heart association stage iv),unstable angina, and severe arrhythmias.

Keywords: chronic obstructive pulmonary disease non-invasive positive pressure ventilation quality of life long-term oxygen therapy
cryobiopsy vs. vats in diagnosis of interstitial lung diseases

Conditions: Interstitial Lung Disease

Summary: the purpose of this study is to assess efficiency and safety of cryobiopsy compared to video-assisted thoracoscopic lung biopsy (vats) in diagnosis of interstitial lung diseases (ild). to that end, this non-interventional study prospectively collects data from patients undergoing routine diagnosis of ild. in some of those patients less invasive diagnostic approaches do not yield a definitive diagnosis. thus, they will ultimately be subjected to vats if this procedure is reasonable. the information gained by this study will help to assess the significance of cryobiopsy in contrast to vats in this particular disease group.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * known or newly diagnosed interstitial lung disease (ild) * indication for lung biopsy for definitive ild diagnosis * informed consent provided exclusion criteria: * age \< 18 years * inability or contraindication to undergo any form of invasive diagnostic procedure associated with diagnosis of interstitial lung disease * severely restricted co diffusion capacity (\<50%) * pregnancy, lactation * any medical, psychological or other condition restricting the patient's ability to provide informed consent * participation in another clinical trial

Keywords: interstitial lung disease diagnosis cryobiopsy video-assisted thoracic surgery lung biopsy
continuous registration of bioimpedance during hemodialysis

Conditions: Dialysis Related Complication; Dehydration

Summary: this studies aims at testing continuous registration of bioimpedance during hemodialysis and comparing the measurement with extracted liquid.

the purpose is to test the sensitivity and specificity of a new electronic patch in the indication of the relative change in the fluid balance. if possible, the change in hydration level should be quantified. the test is done on patients during hemodialysis. extracted amount of fluid is used as the primary reference to the bioimpedance measurements, but other references will also be used. the measurement is made using bioimpedance measured with four electrodes and over a large frequency spectrum. impedance measurements are made every 20 seconds throughout the test period. the measurement is recorded in a memory (flash) on each patch. at the same time as measuring bioimpedance, the temperature in the patch is recorded. after completion of the test, the data is transferred to a computer for analysis. as a reference, extracted amount of fluid, weight change, blood samples and clinical evaluation are used.

Eligibility criteria:
inclusion criteria: * patients for hemodialysis exclusion criteria: * acute in-current disease. * known adverse reaction to medical adhesive
sitagliptin treatment in patients with type 2 dm after kidney transplant

Conditions: Kidney Transplant; Type 2 Diabetes

Summary: this study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. it is also designed to look at the side effects experienced in the transplant population.

within the last six months, the fda has approved sitagliptin phosphate as an oral drug that potentiates the effect of native glp-1 through inhibition of dpp-4. it is approved for treatment of type 2 diabetes in adults as monotherapy or in combination with metformin or a tzd. it has several advantages over extenatide when considering its use in kidney transplant recipients: 1. it is administered orally once a day 2. nausea occurred at a rate of only 1.4% 3. its potential of hypoglycemia is low however, it may not be as potent, in terms of hba1c with % change in hba1c\<1%. in addition there is not a lot of information on gastric emptying, although this is probably not as severe as exenatide, with fewer symptoms of nausea reported. we propose to conduct a pilot study for using sitagliptin in patients who have both type 2 diabetes and who have received a kidney transplant. our objectives are to study the effect of sitagliptin administration on side effect profiles, change in hba1c, and the percentage of patients who require discontinuation of the drug as a result of major changes in immunosuppressant drug levels. the data will be used as preliminary data for a larger study that attempts to prevent or delay the onset of ptdm in kidney transplant recipients. we anticipate treating patients with both impaired fasting glucose and normoglycemia, given the high frequency of ptdm in the post-kidney transplant population.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * most recent hba1c 6.5-10% * 1 year post kidney transplant exclusion criteria: * patients treated primarily with insulin for their diabetes * kidney allograft not functional at entry or estimated creatinine clearance of \<30 ml/min * clinical course complicated by persistent nausea * severe gastroparesis * severe recurrent hypoglycemia (\>1 hypoglycemic episode requiring the help of another person per week). * patients on dialysis therapy * unstable renal function in the preceding 3 months * serum transaminases \>2 times normal at study entry * smokers * pregnant or planning to become pregnant * lactating * recipients of multi-organ transplants * unstable medical conditions which result in multiple hospitalizations or a severely restricted lifestyle * hemoglobin \<10.0g/dl * use of digoxin * patients receiving their primary care outside of unmc * inability to come to follow-up visits as a part of the protocol * patients not taking tacrolimus and sarolimus as part of their immunosuppressive therapy

Keywords: kidney transplant type 2 diabetes sitagliptin